Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

August 8, 2016 by Alan Khadavi

Fevipiprant new asthma pill hailed as a “game changer”

Fevipiprant, also known as QAW039, is a drug being developed by Novartis for the treatment of asthma.  There has been no new asthma pill in nearly 20 years since Singulair (montelukast) was brought to market.  There is a great need for oral asthma medications as many asthma sufferers do not like taking inhaled steroids, which is used as primary treatment prevention.  Many of the new asthma medications now being brought to market are given as injections.

New Asthma Medications

Fevipiprant is an orally available antagonist of the Prostagladin D2 receptor.   Fevipiprant seeks to prevent immune cells called eosinophils into the lungs where they restrict and inflame the airways.  A recent medication called Nucala was recently approved for eosinophilic asthma and it is given as injection. New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Chris Brightling, a professor at the University of Leicester, called fevipiprant “a game-changer for future treatment of asthma”, he led the most recent study published in the British journal, The Lancet Respiratory Medicine.

Two treatment groups of 30 moderate to severe asthmatics were studied, one received fevivpiprant 225 mg twice a day and the other participants were given a placebo.  The participants who received fevipiprant showed a marked decrease in the eosinophils in their sputum (5.4% to 1.1%) over 12 weeks.  Those who took fevipiprant also reported extensive easing of symptoms, the research team said.  No adverse effects were reported.

Brightling said “we already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.”  Larger studies of this prototype drug made by Novartis need to be done before being approved for the clinical market.  Fevipiprant is currently in Phase 3 testing and the hoped for launch date is sometime in 2019.  There is no trade or brand name for fevipiprant (QAW039) yet.

Asthma affects over 300 million people worldwide.  Lifestyle and environmental influences such as tobacco, dust mites, animal dander and pollen are known triggers of asthma.  Because the primary treatment option for asthma is inhaled steroids, many patients are not compliant with medications and are worried about long term side effects.  If approved, fevipiprant would be available in the oral form, there are no significant adverse effects reported to date.  It is too early to speculate on the cost or price of fevipiprant as there are no comparable asthma medications and this would be a new class of maintenance medications.  Always speak to your asthma doctor to see which medication is right for you.

Update February 5, 2021 The Lancet published phase 3 double blinded, randomized, placebo controlled trials (LUSTER-1 and LUSTER-2) to examine the efficacy of fevipiprant in controlling severe asthma. In both trials, fevipiprant modestly improved FEV1 and reduced rates of exacerbations without achieving significance. Fevipiprant was well tolerated though. This may be the end of fevipiprant as a treatment for asthma. Although some modest benefit was seen, its not enough to further pursue this as a treatment option.

Filed Under: Asthma, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page